Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Jennyfer M García-Cárdenas, Alberto Indacochea, David Pesantez-Coronel, Martín Terán-Navas, Ana Aleaga, Isaac Armendáriz-Castillo, Lizbeth Peña Zúñiga, Carla Morán-Erazo, Erik Chávez-Vélez, Andy Pérez-Villa, Andrés López-Cortés, Santiago Guerrero
PURPOSE: Ethnic diversity in cancer research is crucial as race/ethnicity influences cancer incidence, survival, drug response, molecular pathways, and epigenetic phenomena. In 2018, we began a project to examine racial/ethnic diversity in cancer research, with a commitment to review these disparities every 4 years. This report is our second assessment, detailing the present state of racial/ethnic diversity in cancer genomics and clinical trials. METHODS: To study racial/ethnic inclusion in cancer genomics, we extracted ethnic records from all data sets available at cBioPortal (n = 125,128 patients) and cancer-related genome-wide association studies (n = 28,011,282 patients) between 2018 and 2022...
April 2024: JCO Precision Oncology
#2
JOURNAL ARTICLE
Giacomo Montagna, Mary M Mrdutt, Susie X Sun, Callie Hlavin, Emilia J Diego, Stephanie M Wong, Andrea V Barrio, Astrid Botty van den Bruele, Neslihan Cabioglu, Varadan Sevilimedu, Laura H Rosenberger, E Shelley Hwang, Abigail Ingham, Bärbel Papassotiropoulos, Bich Doan Nguyen-Sträuli, Christian Kurzeder, Danilo Díaz Aybar, Denise Vorburger, Dieter Michael Matlac, Edvin Ostapenko, Fabian Riedel, Florian Fitzal, Francesco Meani, Franziska Fick, Jacqueline Sagasser, Jörg Heil, Hasan Karanlik, Konstantin J Dedes, Laszlo Romics, Maggie Banys-Paluchowski, Mahmut Muslumanoglu, Maria Del Rosario Cueva Perez, Marcelo Chávez Díaz, Martin Heidinger, Mathias K Fehr, Mattea Reinisch, Mustafa Tukenmez, Nadia Maggi, Nicola Rocco, Nina Ditsch, Oreste Davide Gentilini, Regis R Paulinelli, Sebastián Solé Zarhi, Sherko Kuemmel, Simona Bruzas, Simona di Lascio, Tamara K Parissenti, Tanya L Hoskin, Uwe Güth, Valentina Ovalle, Christoph Tausch, Henry M Kuerer, Abigail S Caudle, Jean-Francois Boileau, Judy C Boughey, Thorsten Kühn, Monica Morrow, Walter P Weber
IMPORTANCE: Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown. OBJECTIVE: To investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node...
April 25, 2024: JAMA Oncology
#3
JOURNAL ARTICLE
Florence Molinié, Lionel Lafay, Agnès Rogel
No abstract text is available yet for this article.
April 25, 2024: JAMA Oncology
#4
JOURNAL ARTICLE
Javier David Benitez Fuentes, Eileen Morgan, Isabelle Soerjomataram
No abstract text is available yet for this article.
April 25, 2024: JAMA Oncology
#5
REVIEW
Agani Afaya, Sung-Won Kim, Hyung Seok Park, Myong Cheol Lim, Mi Sook Jung, Eun Ji Nam, Ji Soo Park, Joon Jeong, Jai Min Ryu, JiSun Kim, Jihye Kim, Minkyoung Kim, Juhye Jin, Jeehee Han, Soo Yeon Kim, Sun-Young Park, Maria C Katapodi, Sue Kim
Despite increased awareness and availability of genetic testing for hereditary breast and ovarian cancer (HBOC) syndrome for over 20 years, there is still significant underuse of cascade genetic testing among at-risk relatives. This scoping review synthesized evidence regarding psychosocial barriers and facilitators of family communication and/or uptake of cascade genetic testing in relatives from HBOC families. Search terms included 'hereditary breast and ovarian cancer' and 'cascade genetic testing' for studies published from 2012-2022...
April 25, 2024: Familial Cancer
#6
JOURNAL ARTICLE
Mohammad Ali, S N Manjula, Ishfaq Mohiuddin, K Mruthunjaya, Faiyaz Shakeel, Suhail Ahmad Mir, Shahid Ud Din Wani
BACKGROUND AND AIM: Morinda citrifolia fruit juice (noni) is an herbal remedy documented to have antioxidant properties. It has been suggested that prevention of carcinogen-DNA adduct formation and the antioxidant activity of NJ may contribute to the cancer preventive effect. In the present study, the antitumor activity of noni was investigated in the presence of cyclophosphamide (CYL) in vitro and in vivo. METHODS: In vitro breast cancer cells (MDA-MB-468) were used to measure the percentage of inhibition and the IC50 ...
April 25, 2024: Journal of Cancer Research and Clinical Oncology
#7
JOURNAL ARTICLE
Thor S Stead, Connie Y Lu, Abby Geletzke, Elizabeth Butler, Ashley Stuckey, David A Edmonson, Jennifer S Gass
PURPOSE: The skin and/or nipple-sparing approach has become an oncologically sound and desirable choice for women choosing mastectomy. Indocyanine green (ICG) perfusion imaging has been shown to reduce ischemic complications in mastectomy skin flaps. Immediate reconstruction requires a well-vascularized skin flap capable of tolerating full expansion. Identification of the perforating subcutaneous vessels to the skin envelope may allow for better and more consistent blood vessel preservation and flap perfusion...
April 25, 2024: Breast Cancer Research and Treatment
#8
COMPARATIVE STUDY
Comparing symptom clusters in cancer survivors by cancer diagnosis: A latent class profile analysis.
Lena J Lee, Claire J Han, Leorey Saligan, Gwenyth R Wallen
PURPOSE: Research on symptom clusters in oncology is progressing, but knowledge gaps remain. One question is whether the number and types of symptom subgroups (i.e., latent classes) differ based on cancer diagnosis. The purpose of this study was to: (1) identify and compare latent class subgroups based on four highly prevalent symptoms (pain, fatigue, sleep disturbance, and depression), and (2) examine the differences in sociodemographic and clinical factors in the identified latent classes across the seven cancer types (i...
April 25, 2024: Supportive Care in Cancer
#9
EDITORIAL
Antonio Pesce, Nicolò Fabbri, Diletta Iovino, Carlo Vittorio Feo
In this editorial, we have analyzed the historical evolution of rectal and breast cancer surgery, focusing on the progressive reduction of demolitive approaches and the increasing use of more conservative strategies, accompanied by a growing emphasis on perioperative treatments aimed at enhancing surgical outcomes. All of these changes have been made possible due to an increased awareness and understanding of oncological diseases and improved perioperative treatments.
April 15, 2024: World Journal of Gastrointestinal Oncology
#10
Manish Charan, Travis H Jones, Dinesh K Ahirwar, Nandini Acharya, Vish V Subramaniam, Ramesh K Ganju, Jonathan W Song
Despite tremendous advances in oncology, metastatic triple-negative breast cancer remains difficult to treat and manage with established therapies. Here, we show in mice with orthotopic triple-negative breast tumors that alternating (100 kHz), and low intensity (<1 mV/cm) induced electric fields (iEFs) significantly reduced primary tumor growth and distant lung metastases. Non-contact iEF treatment can be delivered safely and non-invasively in vivo via a hollow, rectangular solenoid coil. We discovered that iEF treatment enhances anti-tumor immune responses at both the primary breast and secondary lung sites...
April 17, 2024: bioRxiv
#11
Lei Wang, Yu-Xia Wang, Li-Ping Chen, Ming-Li Ji
[This retracts the article DOI: 10.3892/ol.2016.5230.].
June 2024: Oncology Letters
#12
REVIEW
Vítor Silva, Cristiano Matos
INTRODUCTION: Treatment of cancer has been improved with the discovery of biological drugs that act as immune checkpoint inhibitors. In 2017, FDA designated pembrolizumab, an immune checkpoint inhibitor employed in immunotherapy, as the first tissue-agnostic cancer treatment. OBJECTIVES: To review pembrolizumab's use in oncology, gather and examine the latest discoveries regarding the effectiveness of pembrolizumab in cancer treatment. METHODOLOGY: A literature review was conducted through PubMed(Medline) from January 2015 to December 2023 using "pembrolizumab", "cancer" and "treatment" as search terms...
April 24, 2024: Clinical & Translational Oncology
#13
JOURNAL ARTICLE
Ekin Dila Topaloğlu Ören, Seda Dorukoğlu, Gül Ertem
OBJECTIVE: The study aimed to reveal the approaches to coping with stress of women with breast cancer and the factors predicting these approaches, to determine the prevalence and characteristics of Complementary and Alternative Medicine (CAM), and to examine the relationship between use of CAM and approaches to coping with stress. METHODS: A descriptive and cross-sectional study was conducted among 328 women with breast cancer at a training and research hospital in Türkiye...
April 22, 2024: Enfermería clínica (English Edition)
#14
JOURNAL ARTICLE
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Jörg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua Meeks, Francisco E Vera Badillo, J Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Grünwald, Michael Hölzel, Markus Eckstein
PURPOSE: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS: We established a NECTIN4 -specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108)...
April 24, 2024: Journal of Clinical Oncology
#15
JOURNAL ARTICLE
Bo Zhang, Yang Liu, Jinsong Yu, Xi Lin
Cancer-associated fibroblasts (CAFs) play a pivotal role in cancer progression. This study aimed to explore the roles of CAFs-derived Fibroblast growth factor 9 (FGF9) and Neuro-oncological ventral antigen 1 (NOVA1) in triple negative breast cancer (TNBC) progression. MDA-MB-231 and BT-549 cells were cocultured with CAF conditioned-medium (CAF-CM) or normal fibroblasts conditioned-medium (NF-CM). MTT, EdU, colony formation, wound healing, transwell migration, and invasion assays were employed to determine cell proliferation, migration and invasion, respectively...
May 2024: Drug Development Research
#16
JOURNAL ARTICLE
Zhiyuan Jiang, Qianru Huang, Yujie Chang, Yiran Qiu, Hao Cheng, Mengdi Yang, Shunyi Ruan, Suyuan Ji, Jing Sun, Zhiyu Wang, Shengyuan Xu, Rui Liang, Xueyu Dai, Kejin Wu, Bin Li, Dan Li, Hui Zhao
PURPOSE: Increased expression of leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is associated with immune evasion in breast cancer (BC). The aim of this study to elucidate the role of LILRB2 in BC progression. METHODS: LILRB2 expression in tumor tissues was detected by immunohistochemical staining. Human leukocyte antigen A (HLA-A) expression in BC cells was detected by Western blotting, and HLA-A ubiquitination was detected by immunoprecipitation and histidine pulldown assay...
April 24, 2024: Cellular Oncology (Dordrecht)
#17
REVIEW
William M Gallagher, Christine McCaffrey, Chowdhury Jahangir, Clodagh Murphy, Caoimbhe Burke, Arman Rahman
INTRODUCTION: Histological images contain phenotypic information predictive of patient outcomes. Due to the heavy workload of pathologists, the time-consuming nature of quantitatively assessing histological features, and human eye limitations to recognize spatial patterns, manually extracting prognostic information in routine pathological workflows remains challenging. Digital pathology has facilitated the mining and quantification of these features utilizing whole-slide image (WSI) scanners and artificial intelligence (AI) algorithms...
April 24, 2024: Expert Review of Molecular Diagnostics
#18
Mengting Che, Yuanqiong Duan, Rutie Yin
BACKGROUND: Radiotherapy, a primary treatment for malignant cancer, presents significant clinical challenges globally due to its associated adverse effects, especially with the increased survival rates of cancer patients. Radiation induced heart disease (RIHD) significantly impacts the long-term survival and quality of life of cancer survivors as one of the most devastating consequences. Quite a few studies have been conducted on preclinical and clinical trials of RIHD, showing promising success to some extent...
2024: Frontiers in Oncology
#19
RANDOMIZED CONTROLLED TRIAL
Miriam Ortiz, Maren Luise Schröder, Benno Brinkhaus, Barbara Stöckigt
BACKGROUND: Breast cancer survivors often suffer from diagnosis- and therapy-related long-term side effects, such as cancer related fatigue, restricted stress resilience and quality of life. Walking as a physical activity and mindfulness practice have been shown to be helpful in studies. The aim of this study was to compare the individual experiences and subjectively perceived effects of walking in combination with mindfulness practice with moderate walking alone in breast cancer patients...
2024: Integrative Cancer Therapies
#20
JOURNAL ARTICLE
Shengqi Wang, Jing Li, Shicui Hong, Neng Wang, Shang Xu, Bowen Yang, Yifeng Zheng, Juping Zhang, Bo Pan, Yudie Hu, Zhiyu Wang
BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and chemotherapy still serves as the cornerstone treatment functioning by inducing cytotoxic cell death. Notably, emerging evidence suggests that dying cell-released signals may induce cancer progression and metastasis by modulating the surrounding microenvironment. However, the underlying molecular mechanisms and targeting strategies are yet to be explored. METHODS: Apoptotic TNBC cells induced by paclitaxel or adriamycin treatment were sorted and their released extracellular vesicles (EV-dead) were isolated from the cell supernatants...
April 23, 2024: Journal of Experimental & Clinical Cancer Research: CR
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
